What Does Sprycel Do?
The question of "What Does Sprycel Do?" is a common one for patients with leukemia. Sprycel is a type of drug called a tyrosine kinase inhibitor. This drug works by targeting specific proteins on the leukemia cells that are causing the blood cells to clump together. The side effects of Sprycel can be avoided by taking the tablet on a regular basis.
Dasatinib
You Can Buy Dasatinib and Sprycel On buy-pharma.md or also it available from a pharmacist. The dose should be taken once per day. These tablets should be swallowed whole, and the dose is based on the weight and medical condition of the patient. Patients should discuss the dosage with their healthcare team if they experience any side effects. Dietary restrictions and weight are other important considerations. However, patients should note that the side effects of dasatinib should not prevent them from taking the drug.
Tyrosine kinase inhibitor
Sprycel is a type of medication that belongs to the class of tyrosine kinase inhibitors. Tyrosine kinase inhibitors inhibit the growth and spread of cancer cells by affecting an enzyme called a kinase. Sprycel inhibits the kinase BCR-ABL, which is involved in the growth and spread of ALL and CML cancer cells.
While Sprycel is used to treat Philadelphia chromosome-positive leukemia, it is being studied for other types of cancer. This drug blocks the BCR-ABL protein and some other proteins that may help keep cancer cells from growing. Sprycel is also known by its other names, BMS-354825 and dasatinib. This type of medicine is often prescribed for patients with blood cancer.
Treatment of leukemia
Sprycel is an oral tyrosine kinase inhibitor that blocks BCR-ABL, SRC family, EPHA2 and PDGFR kinases. These molecules cause cancer cells to stop producing certain proteins that fuel their growth. Sprycel has been approved by the U.S. Food and Drug Administration for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
The data from the Phase 2 open-label, nonrandomized trial of SPRYCEL in pediatric patients with newly diagnosed chronic phase CML or imatinib-resistant CML are based on exposure to all doses in the study. Patients in Cohorts 1 and 3 were newly diagnosed with CP-CML or Ph+ CML. The median duration of therapy was 29 months in Cohorts 1 and 2, respectively. Patients with Philadelphia chromosome-positive acute lymphoblastic leukemia were included in Cohort 2.
Side effects
Sprycel is a topical medication that can cause a side effect known as an allergic reaction. Although there is no known risk factor for these side effects, people with sensitive skin or other medications may have a greater risk of serious allergic reactions to the medicine. Talking to your doctor is recommended if you are concerned that you may be experiencing a severe allergic reaction to the drug. Symptoms may include blistering, pain, swelling, or ulceration.
Some common side effects of SPRYCEL may include anemia, low blood cell counts, and fluid retention. Your healthcare provider will monitor your blood counts regularly while taking this medication. If you experience any unusual symptoms or develop a fever, you should call your healthcare provider immediately. Additionally, you should discuss the possible effects of Sprycel with your doctor. One of the most serious side effects of Sprycel is low blood counts. Low blood counts may increase your risk for bleeding, infection, and anemia. Fluid retention may also occur in the eyes, lungs, and abdominal cavity. This may cause a pleural effusion or pericardial effusion.
Drug interactions
There are many potential Sprycel and drug interactions. The most common ones are listed below. These interactions may occur if you take Sprycel at the same time as other medicines, alcohol, or certain types of food. While it is difficult to determine the relevance of these interactions for an individual patient, it is best to limit risks, monitor your treatment, and avoid or minimize interactions as much as possible. Here are a few examples of possible Sprycel and drug interactions.